Mekinist may be available through a mail-order pharmacy. Using this type of service may help lower the drug’s cost and allow you to receive your medication without leaving home. Some Medicare ...

Study is longest Ph III survival follow-up to date of BRAF V600E/K mutation-positive melanoma patients who received a targeted combination therapy Latest data show an estimated 44% of patients ...

Tafinlar and Mekinist are also indicated in more than 35 countries worldwide, including the US and EU, as single agents to treat patients with unresectable or metastatic melanoma with a BRAF V600 ...

Of patients who achieved a complete response with Tafinlar + Mekinist, 19% (n=109) had five-year PFS and overall survival rates of 49% and 71%, respectively, compared with 19% and 34% in the ...

This is the first FDA-approved systemic therapy for first-line treatment of pediatric patients with low-grade glioma with a BRAF V600E mutation.

Tafinlar-Mekinist Combo Wins Tumor-Agnostic Indication for BRAF V600E Solid Tumors Steve Duffy | June 23, 2022 ...

Basel, June 23, 2022— Novartis today announced the US Food and Drug Administration granted accelerated approval for Tafinlar ®+ Mekinist ® for the treatment of adult and pediatric patients 6 ...

NEW YORK — The Food and Drug Administration recently approved Mekinist (trametinib) in combination with Tafinlar (dabrafenib) to treat patients with advanced melanoma that is unresectable (i.e ...

Mekinist should be taken only once daily (either in the morning or evening, at the same time as Tafinlar). The first and second dose of Tafinlar should be taken approximately 12 hours apart.

DORVAL, QC, Dec. 16, 2019 /CNW/ - Novartis is pleased to announce that British Columbia will now fund the combination of Tafinlar ® +Mekinist ® (dabrafenib + trametinib) for adjuvant treatment ...

The findings also showed that this particular sequence of Opdivo plus Yervoy followed by Tafinlar combined with Mekinist produced more durable responses to treatment and was better at preventing ...

The European Medicines Agency (EMA) has approved the MEK-inhibitor trametinib (Mekinist, GlaxoSmithKline) for the treatment of melanoma, following on from the positive opinion the product received ...